Zacks.com on MSN

BMY vs AMGN: Which Biotech Stock Is More Resilient Now?

AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
ALS News Today

COYA 302 trial in ALS expands to Canada after regulatory nod

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...